Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An +15 more
wiley +1 more source
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. [PDF]
Tran B +28 more
europepmc +1 more source
ABSTRACT Alterations in the composition of the gut microbiota have been associated with colorectal cancer (CRC), with growing evidence indicating that specific microbes can have an impact on the tumour microenvironment. In this study, we investigated the associations of an oral pathobiont consortium comprising P. stomatis, F. nucleatum sensu lato and P.
Marina Rubio Garcia +8 more
wiley +1 more source
Low-Dose Interleukin-2 Enhances Activated Suppressor Regulatory T Cells and CTLA-4 and HLA-DR Expression in Chronic Chikungunya Arthritis. [PDF]
Tritsch SR +27 more
europepmc +1 more source
MLMP: A Methylation‐Associated lncRNA‐mRNA Prognostic Signature for Endometrial Carcinoma
ABSTRACT Background Endometrial carcinoma (EC) is one of the most common gynecological malignancies. Aberrant DNA methylation (DNAm) is an important epigenetic alteration involved in cancer progression. Long non‐coding RNAs (LncRNAs) play critical roles in gene regulation and pathological processes.
Hong Kou +10 more
wiley +1 more source
Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma. [PDF]
Zhou Z +5 more
europepmc +1 more source
Intratumoral CTLA‐4 Blockade: Decoupling Local Immune Remodeling From Systemic Toxicity
MedComm – Oncology, Volume 5, Issue 4, December 2026.
Luyan Chen +4 more
wiley +1 more source
ABSTRACT Background Restarting immune checkpoint inhibitors (ICIs) after an immune‐related adverse event (irAE) requires balancing toxicity against antitumor benefit. Prior reviews often mixed post‐irAE restart with retreatment after progression or combined cohorts with case reports. This systematic review evaluated cohort evidence on ICI restart after
Xinwei Chen +6 more
wiley +1 more source
CTLA-4 and targeted immunotherapy-a key link in the systemic influence of periodontitis: a mini review. [PDF]
Thanigaimalai A +4 more
europepmc +1 more source
Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study
ABSTRACT Background Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with high recurrence rates and limited prospective data to guide postoperative management. While immune checkpoint inhibitors (ICI) have reshaped melanoma treatment, their survival impact in resected HNMM remains poorly defined.
Dary Phen +9 more
wiley +1 more source

